|Bid||3.02 x 5000|
|Ask||3.03 x 1000|
|Day's range||2.99 - 3.15|
|52-week range||2.83 - 10.06|
|PE ratio (TTM)||N/A|
|Earnings date||16 Jan 2018 - 20 Jan 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||21.50|
Advaxis, Inc. , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that company management will participate in the Jefferies 2017 London Healthcare Conference taking place November 15-16, 2017 in London, UK.
Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, held its annual Investor & Analyst Day this week with clinical investigators and company leaders providing updates and details on the company’s Lm Technology™ and nine development programs. Mark Stein, MD, of Rutgers Cancer Institute of New Jersey, discussed encouraging preliminary immunological data generated from Advaxis’ prostate cancer program with ADXS-PSA in combination with Keytruda® (pembrolizumab). Dr. Stein reported that ADXS-PSA when used as monotherapy was shown to stabilize disease progression in ~30% (4/13) of patients in the dose escalation phase of the study.